Quantification of Two Fluorophores’ Concentration Ratio in a Mice Model in Preparation for a Proposed Method for Early Detection of Alzheimer’s Disease †

Osnat Harbater 1, Margalit Efrati 2 and Israel Gannot 1,3, *

1 Department of Biomedical Engineering, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel; osnatsr@yahoo.com
2 Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel; mefrati@post.tau.ac.il
3 Department of Electrical and Computer Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

* Correspondence: igannot1@jhu.edu

† This paper is an extended version with additional data and updated references of a paper published in the In Optical Fibers and Sensors for Medical Diagnostics and Treatment Applications XV conference, San Francisco, CA, USA, 7–8 February 2015.

Received: 27 March 2018; Accepted: 3 May 2018; Published: 8 May 2018

Abstract: Many biomedical applications require concentration measurements of biological compounds, which may be achieved using targeted fluorescent probes. It has been shown that the ratio between amyloid-Beta and tau protein in the cerebrospinal fluid (CSF) is a good indicator of incipient Alzheimer’s disease (AD). We have previously proposed a method that can accurately estimate the concentration ratio of these two proteins without the need to collect CSF samples: Fluorescent probes are injected to the blood and bind to the CSF biomarkers. A miniature needle with an optical fiber excites the fluorescent probes and collects the fluorescence emission. The concentration ratio between the proteins is estimated, and used for diagnosis of incipient AD. We present here the results of the method’s concentration ratio estimation during trials performed on mice. Miniature tubes containing two fluorescent probes in several concentration ratios were implanted in two locations in the mice: subcutaneously, and deeper in the abdomen. The fluorescent probes were excited and the fluorescence intensity was measured. The concentration ratios were estimated from the fluorescence intensities with an average error of less than 20%. This study is a step towards the demonstration of the method in in vivo studies in mice with markers in the bloodstream/CSF.

Keywords: fluorescence; disease markers; Alzheimer’s early diagnostics; CSF biomarkers

1. Introduction

Alzheimer’s disease (AD) is the most frequent type of dementia [1], which includes a variety of diseases such as AD, vascular dementia, dementia with Lewy bodies, Parkinson’s disease, and more. Dementia is caused by the death or malfunction of nerve cells in the brain, which results in a decline in memory and in several cognitive abilities. In AD, the pathological abnormalities are characterized by a gradual loss of axons and neurons, together with the presence of neurofibrillary tangles and amyloid plaques in the brain. According to the new criteria for diagnosing AD [1], the disease includes three stages: preclinical AD, Mild Cognitive Impairment (MCI) due to AD, and dementia due to AD. During the preclinical AD stage, which may last up to 20 years, no cognitive decline and memory loss symptoms occur. However, the pathogenic process in this stage already induces measurable changes in the brain, in the cerebrospinal fluid (CSF), and in the blood. Therefore, diagnostic tools for early
detection of the disease, based on these pathological expressions, may have a significant advantage. Currently, there is no treatment available for preventing, or curing AD, but there are enormous efforts, worldwide, towards developing treatment. In order for treatment to be effective, there is a crucial need for early detection of AD.

One of the promising methods for early detection of AD uses measurements of cerebrospinal fluid (CSF) amyloid-beta and tau protein concentrations. Due to the accumulation of amyloid-beta in the brain, there is a significant reduction in CSF Aβ42 levels. On the other hand, the release of tau and phosphorylated-tau during the neurodegeneration and the neurofibrillary tangles creation, increases the levels of these proteins in the CSF [2]. As a result, the CSF concentration of the Aβ42, total tau, and p-tau is highly correlated with early diagnosis of AD.

Several groups have shown the possibility of predicting the development of MCI to AD, years before the clinical diagnosis of the disease, based on these biomarkers [2–6]. Hannson et al. [3] showed that a combination of CSF T-tau and Aβ42/P-tau ratio yielded high sensitivity and specificity for detection of incipient AD in patients with MCI who were followed for a period of 4–6 years. The optimum cutoff value was Aβ42:P-tau < 6.5 for the incipient AD patients at baseline. The follow-up of this study was extended [4] for up to 11.8 years (median = 9.2 years). Using a cutoff value of 6.16 for the Aβ42:P-tau ratio, they predicted the future development of AD dementia with a sensitivity of 88% and a specificity of 90%.

A multi-center research [6] covering 12 centers in Europe and in the USA and including more than 1500 individuals (with AD, MCI and healthy controls) followed MCI patients for at least two years. A comprehensive statistical analysis was performed in order to determine the possibility to predict incipient AD in MCI patients based on their Aβ42, total tau and P-tau CSF levels. Their results indicated that the combination of Aβ42:P-tau ratio and total tau identified incipient AD with a sensitivity of 83% and specificity of 72%. These results are highly significant but are less accurate than the previously reported results. Possible reasons are large variability between the centers, lack of standardization, and relatively short follow-up.

In order to measure the Aβ42, total tau, and P-tau CSF concentrations, a lumbar puncture process was performed and CSF samples were collected. The lumbar puncture procedure has many risks, side effects, and complications [7], which limit its potential to be an annual test for early AD diagnosis. This limitation may be resolved by less invasive methods that enable measurements of the CSF protein concentrations using optical techniques.

Many optical techniques were developed for quantifying tissue components, proteins and drugs. Most of the methods are based on transmission or diffused reflection spectroscopy. When quantifying tissue components in vivo, these methods usually use near-infrared (NIR) wavelengths, especially in the 650–900 nm range where the absorption of water and fat is rather low. Therefore, spectroscopy-based methods may not be suitable for quantifications of proteins whose absorption peaks do not fall in this range of wavelengths.

Fluorescence sensing methods may be used for quantifying the concentration of biological molecules, which may bond to extrinsic fluorophores. However, in most presented methods, the concentration estimation required usage of light propagation models combined with a priori knowledge of the tissue optical properties [8–14] or the usage of complex tomography systems [15–20], which are less suitable for endoscopic applications. In addition, most of these methods usually involve an additional calibration process by normalizing the emission against the excitation [21], or normalizing multiple emission wavelengths [22].

Several groups have developed fluorescent probes suitable for the detection of Alzheimer’s disease. Many groups have focused on developing fluorescent probes with high affinity to amyloid-beta protein, which may image the amyloid plaques in the brain. Raymond et al. [23] have synthesized and tested a family of dyes (NIAD) that emit a characteristic fluorescence signal only when bound to amyloid-beta protein. They have showed changes in the fluorescence quantum yield, lifetime and emission spectra due to the binding of the probe to amyloid-beta. Hintersteiner et al. [24]
have described a high quantum yield NIR probe AOI987, penetrating the blood–brain barrier. They demonstrated the interaction of the probe with amyloid plaques in APP23 transgenic mice in vivo and showed increasing fluorescence intensity with increasing plaque load. Zhang et al. [25] designed and synthesized curcumin based NIR probes. The CRANAD-58 probe showed significant fluorescence property changes upon mixing with both soluble and insoluble Aβ species in vitro. They tested it in vivo and revealed that CRANAD-58 was capable of differentiating transgenic and wild-type mice as young as four months old. They have also designed the CRANAD-17 probe, which was capable of inhibiting Aβ42 cross-linking induced by copper. This raises a possibility for CRANAD-17 to be considered for AD therapy.

Okamura et al. [26] report the optical profiles of THK-265, which has high binding affinity to amyloid plaques. They demonstrated that amyloid deposits in AβPP transgenic mice could be detected after intravenous administration of THK-265. They reported significantly higher fluorescence intensity in the brain of AβPP transgenic mice than in those of wild-type mice. Schmidt et al. [27] have also used THK-265 to develop and test a procedure for cerebral amyloid deposits visualization. They demonstrated in vivo the correlation between the intensity of the THK-265 signal and the plaque burden, indicating its utility for direct monitoring of Aβ aggregation progression. Cui et al. [28] report the synthesis, characteristics, and biological evaluations of a series of donor–acceptor molecules (DANIRs) as smart NIRF imaging probes for Aβ plaques in AD. These probes were proved to have affinity to Aβ plaques ex vivo, in vitro, and in vivo, with a significant fluorescence intensity increase and a blue-shift in the emission spectra.

Other groups have tried to develop fluorescent probes with affinity to tau proteins. Maruyama et al. [29] developed a class of tau ligands (PBBs) for optical and PET imaging. These included PBB5, a near-infrared fluorescent probe, which could assess tau accumulation in living mouse models. They demonstrated strong fluorescence of PBB5 in Tg mice expressing a single human four-repeat tau isoform (PS19) relative to non-Tg WT mice in the central nervous system (CNS) suggesting a concentration of this tracer in the PS19 spinal cord. Kim et al. [30] designed a NIR ratiometric probe, CyDPA2 that targets Tau aggregates. They evaluated it in vitro and ex vivo and reported an enhancements of absorption ratio and fluorescence intensity in a p-Tau concentration-dependent manner. In addition, fluorescence microscopy and gel staining studies demonstrated CyDPA2-labeled Tau aggregates.

In a previous report [31], we proposed an optical method that enables measurements of the CSF biomarker concentrations utilizing fluorescence probes, without the need to perform a lumbar puncture. This method is less invasive and has minimal risk, pain, and side effects. The method includes several stages. First, fluorescent probes [23–30,32], which bind specifically to the two biomarkers in the CSF, are injected to the blood. Second, a miniature needle with an optical fiber is inserted into the epidural fat, which is located several millimeters from the CSF, without penetrating the dura matter. The fluorescent biomarkers are then excited by a laser, which reaches the CSF through the optical fiber located inside the needle. Finally, the fluorescence intensities of both biomarkers are measured and used for the estimation of the biomarkers concentration ratio.

Since this optical method does not require CSF collection, the dura matter is not penetrated and a smaller needle may be used. Therefore, the lumbar puncture risks, which include CSF leakage, traumatic taps, spinal cord injuries, and severe headaches, are significantly reduced. In addition, as opposed to other similar optical methods [12,13] the concentration ratio estimation using this method does not require a priori information about the tissue optical and anatomical properties.

In our previous report [31] we introduced a theoretical model that enables to create the relation between the measured fluorescence emission and the biomarkers concentration ratio. The method was validated using Monte Carlo simulations and its accuracy was tested in vitro using multi-layered tissue phantom. Here we further assess the method’s accuracy using mice. Miniature tubes containing two fluorescent probes with several concentration ratios were implanted in the mice. The tubes were inserted into two different locations: subcutaneously, and deeper in the abdomen. The fluorescent probes were excited separately and their fluorescence intensity was measured. Using a simple
calibration curve, the concentration ratio of the fluorescent probes in each tube was extracted. The extracted ratios were compared to the true ratios and an error analysis was performed.

2. Materials and Methods

2.1. Fluorescent Probes

Several fluorescent probes with high affinity to amyloid-beta and tau protein were described in the Introduction [23–30,32]. However, these probes are still under development and are not commercially available, off the shelf products, hence could not be obtained. Therefore, we decided to test our method and verify the accuracy of the concentration ratio estimation using two fluorescent probes that may be purchased easily.

The optimal fluorescent probes should have separate absorption spectra, both in the range of 750–850 nm, where the changes in the absorption and scattering properties of the tissue are negligible. According to this requirement, Cy7 azide and Cy7.5 azide (Lumiprobe, Hallandale Beach, FL, USA), with absorption peaks at 750 and 788 nm and emission peaks at 773 and 808 nm, respectively, were chosen. The extinction coefficients of Cy7 and Cy7.5 are 199,000 and 223,000 $\text{M}^{-1}\text{cm}^{-1}$ and the quantum yield of Cy7 is 0.3. The value of the quantum yield of Cy7.5 was not given by the manufacturer.

Fluorescent samples were prepared with different concentrations between 50 and 900 nM, mixed with concentration ratios (Cy7:Cy7.5) between 1:2 and 1:14. These ratios cover the range of expected concentration ratio between amyloid-beta and P-tau proteins, for MCI patients developing AD, other dementia, or stable MCI.

2.2. Animal Studies

In order to verify the method’s accuracy in animal models, miniature tubes containing fluorescent samples were implanted subcutaneously and abdominally in mice. The miniature tubes were 7 mm long, with 1.7 mm outer diameter and 1 mm inner diameter. They were filled with approximately 5 $\mu$L of the fluorescent samples. The tubes were then sealed at both ends using adhesive.

Five C57BL/6 mice were anaesthetized using intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Two incisions of 3–5 mm were performed on each mouse. One incision was made in the skin near the hind leg of the mouse. A subcutaneous pocket was created and a tube was inserted into the pocket. The pocket was then closed using a 9-mm AutoClip. A second incision was made in the abdomen area of the mouse. This incision was deeper than the subcutaneous one, enabling insertion of the tube a few millimeters deep in the mouse tissue, thus located below skin, muscle and fat tissues. This incision was also closed using a 9-mm AutoClip, which prevented any bleeding. The two fluorescent tubes measured directly after implantation, as will be detailed in the Sections 2.6, 2.7 and 3.2. Anesthesia lasted up to three hours, during which the implantation and fluorescence measurements were performed. When necessary, an additional dose of ketamine (50 mg/kg) was administered to the mouse subcutaneously. All mice were sacrificed by cervical dislocation. All the experimental procedures were approved by the Animal Care Committee of Tel Aviv University (approval number: 034_b8007_26).

2.3. Reference Phantom

A reference phantom required for the calibration process was composed of polyester resin with Titanium Dioxide, according to the protocol described by Firbank and Delpy [33]. Titanium dioxide was added in order to increase the scattering coefficient of the polyester, with a 0.53% titanium dioxide mass percentage. The reference phantom was squared with 2.7 mm thickness and the length of the side was 35 mm.
2.4. System Setup

The samples were excited with a mode-locked, Ti:Sapphire femtosecond laser (Tsunami, Newport/Spectra-Physics, Santa Clara, CA, USA), with 80 MHz repetition rate, pumped by a 5 W, 532 nm laser (Millenia vs., Newport/Spectra-Physics). The laser was tuned to 750 nm for the cy7 excitation and 800 nm for the cy7.5 excitation. The excitation beam was split to a fast photodiode (PHD-400, Becker & Hickl GmbH, Berlin, Germany) for signal synchronization, and to the center fiber bundle of a fluorescence inspection probe (Oriel 77558, Newport, Santa Clara, CA, USA). The Oriel inspection fiber has a central core with a fiber bundle that carries the excitation radiation to the samples. The core is surrounded by a ring of fibers that collect and deliver the fluorescence from the sample to the output channel. The source detector separation, between the central core (input) and the fiber ring (output), was less than 1 mm. The collected fluorescence is delivered through the distal end of the output channel into a filter wheel switching between a band-pass filter FF01-780/12 (Semrock, Rochester, NY, USA) for the Cy7 and long-pass filters RG830 and RG850 (Newport) for the Cy7.5 collection. The emission was measured using a fast photomultiplier tube (PMT) head (H7422P-50, Hamamatsu, Japan). The PMT was controlled using the DCC-100 detector controller (Becker & Hickl GmbH). Data acquisition was accomplished using the TCSPC module (SPC-730, Becker & Hickl GmbH) synchronizing between the SYNC signal arriving from the photodiode and the constant fraction discriminator (CFD) signal from the PMT.

2.5. Calibration Process

A calibration process was performed prior to the animal fluorescence measurements of the miniature tubes. For the calibration process five fluorescent samples were prepared, covering the range of ratios that were measured during the experiment. The samples were placed in sealed cuvettes and the reference phantom was placed above them. The fluorescence energy emitted by these samples was measured at two excitation wavelengths, one for each fluorophore, with the appropriate emission filter. For each measurement, the total number of photons measured by the TCSPC system was used as the fluorescence energy value. A calibration curve of fluorescence energy ratio versus concentration ratio was created based on these measurements.

2.6. Intensity Ratio Measurements

Five mice were anesthetized and implanted each with two fluorescent tubes—subcutaneous and deeper in the abdomen. Two of the tubes were excluded due to problems with the location of the implantation. Eventually the experiment included a total of eight tubes with eight different fluorescent ratios. The fluorescence emission of the probes in the tubes, covering ratios in the range of 1:2 to 1:14, was measured using the fluorescence inspection probe. Four tubes were located subcutaneously and four were located deeper in the abdomen of the mouse. When necessary, the mice were shaved prior to the fluorescence excitation.

The fluorescence measurements were repeated several times for each fluorescent tube. The location of the fiber bundle on the mouse skin surface was changed for each excitation in order to test varying tube depths. After each location change of the fiber bundle, a time-resolved fluorescence intensity was taken in order to ensure that the fluorescent tube is in the imaged photon path. In cases where very low fluorescence intensity was measured the fiber bundle was relocated. In other cases, high intensity was measured but a Gaussian-shaped, time-resolved curve without the expected fluorescence lifetime decay was measured, thus indicating that the collected photons are only resulting from laser reflections, and not from fluorescence. In those cases, the fiber bundle was relocated again until a typical fluorescent lifetime curve was measured. The measured energy ratio was then converted to a concentration ratio value using the calibration curve and compared to the true concentration ratio value.
2.7. Intensity Time-Resolved Measurements

Fluorescence intensity time-resolved measurements were taken from tubes implanted both subcutaneously and in the abdomen. The time-resolved curves were measured using the TCSPC system.

3. Results

3.1. Concentration Ratio Estimation

Initially, a calibration process was performed using a polyester reference phantom before measuring the fluorescent samples in the mice. A calibration curve was created and used for estimating the concentration ratios of the fluorescent tubes located subcutaneously in the hind leg and deeper in the abdomen. Table 1 summarizes the data of the eight fluorescent tubes used in the animal experiments, detailing the number of the fluorescent tube, its location, its true and estimated concentration and the estimation errors. Figure 1 presents the estimated concentration ratio versus the true concentration ratio. Each data point is the average estimated value of four to six measurements (performed on different excitation locations on the mouse skin surface) with its 90% confidence interval. The total number of measurements performed on the eight tubes was 41. The data points of the tubes implanted subcutaneously are represented in Figure 1 using the star symbols and the abdomen tubes are represented using the circle symbols. The dotted lines represent the true ratio values with 15% error value and the dotted lines represent the true ratio values with 35% error value. The mean absolute error of the estimated values presented in Figure 1, is 19.86%, with a standard deviation of 14.04%. When calculating the mean error (as opposed to the mean absolute error), which averages the over estimations and the under estimations, the mean error is 0.69% with a standard deviation of 25.45%. This result indicates that there wasn’t a consistent tendency neither to overestimation nor to underestimation. Therefore, we assume that the reference phantom had more or less the same attenuation as the mouse tissue, although it may have had a flatter absorption spectrum than the mouse tissue. Actually, if the results did show a clear trend for overestimation the accuracy could have been improved using a correction factor. Unfortunately, this cannot be done in our case, but additional experiments, with different reference phantoms, should be performed for complete validation.

![Figure 1. The estimated concentration ratio as a function of the true concentration ratio. The solid line represents the true ratio values. The star symbols represent the average estimated ratios of the subcutaneous tubes with their 90% confidence interval. The circle symbols represent the average estimated ratios of the abdomen tubes with their 90% confidence interval. The dotted lines represent the true ratio values with 15% errors and the dash-dotted lines represent the true ratio values with 35% errors.](image-url)
Table 1. Animal concentration ratio estimation results summary.

| c | Location  | True Concentration [µM] | Estimated Concentration [µM] | Estimation Error [%] | Absolute Estimation Error [%] |
|---|-----------|-------------------------|-------------------------------|---------------------|-------------------------------|
| 1 | Subcutaneous | 7.1                     | 7.11                          | 0.11                | 0.11                          |
| 2 | Abdomen    | 13.92                   | 13.90                         | −0.13               | 0.13                          |
| 3 | Subcutaneous | 11.11                   | 13.99                         | 25.92               | 25.92                         |
| 4 | Abdomen    | 2.82                    | 3.38                          | 19.96               | 19.96                         |
| 5 | Abdomen    | 3.57                    | 4.86                          | 36.20               | 36.20                         |
| 6 | Subcutaneous | 5.02                    | 3.82                          | −23.96              | 23.96                         |
| 7 | Subcutaneous | 5.76                    | 4.82                          | −16.39              | 16.39                         |
| 8 | Abdomen    | 9.50                    | 6.06                          | −36.23              | 36.23                         |
|    | Average    |                         |                               | 0.69                | 19.86                         |

3.2. Abdomen vs. Subcutaneous Tubes

The fluorescent tubes were implanted in two locations—subcutaneously and in the abdomen. It is interesting to investigate if and how these locations affected the accuracy of estimation. The tubes implanted subcutaneously were located in a depth of less than 1 mm under skin surface, whereas the tubes implanted in the abdomen were implanted in a depth of 1–5 mm. It is worth mentioning that in some cases where the mice fur was rather thick, the mice were shaved, while in other cases the fur wasn’t removed. The shaving was performed in order to reduce the attenuation caused by the thick black fur. The shaving was performed both for the subcutaneous tubes and the abdomen tubes. Since the fluorescence intensity ratio was calculated, and it is assumed that the absorption and emission spectra of the fur is almost flat in the used wavelengths, the shaving should not affect the accuracy of the results. The shaving only assisted in achieving higher fluorescence intensities, reducing the measurement time and perhaps increasing the signal to noise ratio. In addition, although the distance of the subcutaneous tubes from the mouse skin was less than the distance of the abdomen tubes, the thickness of the fur in the subcutaneous tubes was higher than in the abdomen. This is due to the fact that the fur in the leg area, which was chosen for the subcutaneous implantation, is thicker than the fur in the abdomen area. Therefore, although the energy attenuation due to the mouse tissue was rather small in the subcutaneous tubes, there was additional attenuation due to the fur. When comparing the mean error in the subcutaneous tube with the abdomen tubes, as presented in Figure 2a, we notice a slight overestimation in the abdomen tubes (4.95% ± 31.22%) compared to a slight under-estimation in subcutaneous tubes (−3.58% ± 22.08%). However, in our opinion this is not due to higher effective attenuation in the subcutaneous tubes, since in most subcutaneous tubes the fluorescence energy measured was higher than the abdomen tubes. Furthermore, it is noticeable in Figure 2a that when taking into account the standard deviation, there is a complete overlap between the subcutaneous and the abdomen errors. In addition, the results are based only on measurements of 4 tubes from each type. It may also be noticed in Figure 1 that both types of tubes showed overestimation in some cases and underestimation in others. Therefore, we assume that the negative mean error in the subcutaneous tubes and the positive mean error in the abdomen tubes do not necessarily imply a consistent underestimation or overestimation, correspondingly.

On the other hand, when looking at the mean absolute error, as presented in Figure 2b, we do see a trend of higher absolute errors in the abdomen tubes compared to the subcutaneous tubes. The mean absolute error for the abdomen tubes was 23.13% ± 17.14% and for the subcutaneous tubes: 16.59% ± 11.73%. This is also noticeable in Figure 1, where the star symbols representing the subcutaneous data are all in the range of about 25% error, while two out of four circle symbols representing the abdomen data have errors of about 35%. The higher absolute errors in the fluorescence measurements taken from the abdomen tubes are not surprising and are actually expected. As mentioned earlier, the tissue overlying the fluorescent tubes is thicker for the tubes implanted in the abdomen. The thick tissue causes more absorption and scattering events thus increasing the effective attenuation. As a result, the intensity of the fluorescence signal decreases and the signal to noise ratio decreases too, resulting in higher errors. In addition, in some
cases, the fluorescence intensity was so low, that it was very difficult to locate the tube and measure the fluorescence signal.

Figure 2. (a) The mean error of estimated concentration ratio (circle symbols) with their 90% confidence interval, for the abdomen tubes (purple) and subcutaneous (blue); (b) the mean of absolute errors of estimated concentration ratios (circle symbols) with their 90% confidence interval, for the abdomen tubes (purple) and subcutaneous (blue).

3.3. Sensitivity and Specificity

Several studies have defined a Aβ42:P-tau ratio cutoff value to differentiate between patients developing AD and patients with stable MCI or with other dementias. For example, Buchhave et al. [4] used a cutoff value of Aβ42:P-tau < 6.16 and predicted the future development of AD in MCI patients within 9.2 years (range 4–12 years) with a sensitivity of 88% and a specificity of 90%. The same group used in an earlier study [3] a cutoff value of Aβ42:P-tau < 6.5 for predicting the future development of AD in the same patients within 5.2 years (range 4–6.8 years). These cutoff values may be used as an example for calculating the specificity and sensitivity of our method. The implanted fluorescent tubes were divided according to their true Cy7.5:Cy7 concentration ratio, to two groups: over/under the ratio cutoff value. These two groups were created once with the lower cutoff value (<6.16), which is a cutoff value for early AD diagnosis (9.2 years) and with the second cutoff value (<6.5), which is the cutoff value for a less early AD diagnosis (5.2 years). An estimated concentration ratio was received for each fluorescence ratio measurement of each tube and compared to the cutoff value. A total of 41 estimated concentration ratios were compared to the cutoff value and used for dividing 41 data points to two groups—over/under the cutoff value. These 41 values were compared to their corresponding true values of the concentration ratio. The data points were divided to 4 groups: TN (true negative), FN (false negative), TP (true positive) and FP (false positive). The results according to each cutoff value are presented in Table 2. For both cutoff values the sensitivity was 100%, meaning that all simulated AD ‘patients’ were diagnosed successfully. The specificity for the higher cutoff value was 82% and for the lower cutoff value was 88%. This result is due to an underestimation in one of the abdomen tubes, which resulted in some FP cases. Obviously, there were more FP cases for the higher cutoff value than for the lower value, resulting in a better specificity in the lower cutoff value.
### Table 2. Sensitivity and specificity calculation.

| Cutoff Value          | TN | FN | TP | FP | Sensitivity | Specificity |
|-----------------------|----|----|----|----|-------------|-------------|
| concentration ratio < 6.5 | 14 | 0  | 24 | 3  | 100%        | 82%         |
| concentration ratio < 6.16 | 15 | 0  | 24 | 2  | 100%        | 88%         |

#### 3.4. Time-Resolved Results

Our proposed method involves with fewer risks and side effects than the lumbar puncture process required for CSF collection and for the measurement of amyloid-beta and tau concentration ratio. However, the method still requires an insertion of a needle to the epidural fat in the lumbar section. A feedback system for the needle distance from the CSF can assist in reducing almost completely any complications and risks involved in such a procedure.

Fluorescence lifetime measurements, which may be taken simultaneously with the fluorescence intensity measurements, may provide the basis for such a feedback system. The fluorescence intensity time-resolved curve is affected both by the intrinsic fluorescence lifetime value and by the photon propagation time. The propagation time depends on the tissue optical properties and on the physical distance between the fluorophore and the source and detector. Since the shape of the time-resolved curve is affected by the distance between the fluorophore and the source and detector we can utilize this curve in order to extract the distance of the needle from the CSF. The extracted distance will provide physicians with real-time information about the needle location, thus avoiding penetration of the dura matter.

In our previous report [31] we demonstrated in vitro the effect of variations in the thickness and scattering coefficient of the overlying phantom layer on two features extracted from the fluorescence intensity time-resolved curve. The first feature is $t_{\text{max}}$, which represents the time in which the intensity reached its maximal value and is related directly to the photon path-length. The value of $t_{\text{max}}$ increases with an increase in the thickness of the overlying medium due to the longer photon path-length required for the fluorescent photons reach the detector. The second feature is the absolute value of the slope of the decaying part of the intensity curve, in logarithmic scale, which decreases with an increase in the thickness of the overlying medium. In other words, there is a steeper decline in the intensity in thin phantoms or tissues compared to the thicker phantoms or tissues. When the thickness of the overlying media increases, there are more scattering events causing more photons arriving at later times, thus reducing the absolute slope of the intensity decay curve.

The time-resolved curves were measured using the TCSPC system during the animal experiments. The fluorescent tubes implanted in the abdomen were located deeper than the tubes implanted subcutaneously. Since the photon path length of the abdomen tubes is bigger than in the subcutaneous tubes, $t_{\text{max}}$ is expected to be higher too. Figure 3 presents the time-resolved fluorescence curve measured from the two tubes implanted in one of the mice: the abdomen tube and the subcutaneous tube. The time-resolved curves were normalized in order to emphasize the difference in $t_{\text{max}}$. As expected, the time in which the abdomen fluorescence reaches its maximal value is higher than the time in which the subcutaneous fluorescence reaches the maximum value: $t_{\text{max}}$ (abdomen) = 1.28 ns and $t_{\text{max}}$ (subcutaneous) = 1.15 ns.

The absolute value of the slope of the intensity decay curve, in logarithmic scale was also calculated for both cases. For the subcutaneous tubes the absolute value of the slope was 0.75 [1/ns], and for the abdomen tubes the absolute slope was 0.74 [1/ns]. As expected, the absolute value of the slope decreases with an increase in the thickness of the tissue overlying the fluorescent tubes.
Figure 3. Time-resolved intensity curve. The triangle symbols represent the subcutaneous fluorescence curve and the circle symbols represent the abdomen fluorescence curve.

4. Discussion

A method for early detection of Alzheimer’s disease using fluorescent probes in the CSF was previously presented by us [31] and validated in vitro and ex vivo. We have further tested and verified the method’s accuracy and performance in animals, in this paper. Although the fluorescent probes were not injected directly to the blood and measured in the CSF as the method proposes, the experiments in this study were an additional important step towards testing the method in an AD animal model. Here we implanted tubes with fluorescent samples into two locations—subcutaneous and in the abdomen. The tubes with the clear fluorescent sample simulate the clear CSF layer, and the overlying tissue simulates the epidural fat layer. Since the abdomen tissue of the mouse consists mainly of fatty tissue, we can assume that the optical properties of the abdomen are similar to the epidural fat in the lumbar section. The experiments were performed also on a live tissue with blood flow and other vital signs, therefore making this a good model for the next in vivo step.

The accuracy of the estimation of the ratio between two fluorescent probes was tested for a large range of ratios using these experiments, with an average estimation error of 19.9%. In our previous experiments [31], performed in vitro on polyester phantoms and ex vivo on chicken breast tissue, the average estimation error was lower. It was less than 5% for the in vitro and 11% for the ex vivo experiments. One can notice that there is an increase in the mean error with an increase in the complexity of the overlying medium. This result indicates that the optical properties of the reference phantom, which is used for creating the calibration curve, are not sufficiently close to the properties of a live tissue. The reference phantom is made of polyester resin with titanium dioxide, thus its scattering [33] is similar to the scattering of human tissue, which has a rather flat scattering spectra in the NIR range [34]. On the other hand, the absorption coefficient of human tissue varies in the NIR range with some peaks in the 700–800 nm range. These absorption peaks do not exist in the polyester absorption spectra, and therefore the polyester reference phantom differs in its absorption spectra from a living tissue, in mice or human. We can assume that chicken tissue has more features in its absorption spectra that are similar to human spectra, and obviously living mice are even more similar. The concentration ratio estimation relies on the fact that the optical properties variation in the 700–800 nm range is negligible, and the energy attenuation due to photon propagation is identical.
in these wavelengths. Therefore, there may be inaccuracies when calculating the ratio based on a calibration curve, which was created using a medium with a different absorption spectrum than the measured tissue. Nevertheless, the errors are still rather small and reasonable. The system’s accuracy may be improved using a different reference phantom, which better resembles the human tissue optical properties, for instance by adding an absorber, such as blood to the polyester. Such an absorber may assist in creating an absorption spectrum similar to the human tissue spectrum.

The fluorescent probes that were implanted subcutaneously had slightly lower estimation errors compared to those implanted deeper in the abdomen. This was explained by the low fluorescence intensity in the abdomen tubes, caused by a thicker overlying tissue. The decrease in the fluorescence intensity caused a lower signal to noise ratio and bigger errors. In addition, the concentration ratio estimation is based on the assumption that the measured fluorescence intensity ratio is affected mainly by the concentrations of the fluorophores and that the energy attenuation due to photon propagation is identical in both wavelengths. However, there are some differences in the absorption and scattering coefficients between the wavelengths used for the excitation of the two fluorophores, and therefore the errors in the concentration ratio estimation increase with an increase in the tissue thickness. Since the abdomen tubes have thicker overlying tissue, the inaccuracy that results from not taking into account photon propagation attenuation has a higher effect, causing bigger errors. There are several actions that may be helpful in avoiding high errors in thick tissue. The first is obviously to avoid performing measurements when there are high distances between the needle and the CSF. This may be done by slow insertion of the needle until a sufficiently high fluorescence signal is measured, with an acceptable signal to noise ratio. In addition, we presented the option to use the fluorescence time-resolved measurements for estimating the distance between the needle and the CSF, and the scattering coefficient. These two estimated values may be used as a correction factor that takes into account the tissue thickness and its optical properties without totally neglecting the photon propagation attenuation.

Although in some cases, the ratios were estimated with an error of 35%, the sensitivity and specificity still remained high. This may be explained by the fact that for low concentration ratios, an error of 35% still resulted in a relatively low difference between the true and estimated ratio. For instance, in one of the cases, the true ratio was 3.57 and the estimated ratio was 4.86, which is equivalent to 36% error. However, the difference between the true and estimated ratio is 1.29, a rather low difference that will not cause false predictions. In the high concentration ratios, the big errors caused a larger difference between the true and estimated ratio values, but the cutoff value was relatively distant from the true ratio. As a result, in those cases, even big errors did not cause too many false predictions. On the other hand, the concentration ratio values that were close to the cutoff value were estimated with a very high accuracy so the sensitivity and specificity remained high. We can assume that our method requires high accuracy in ratios that are close to the cutoff ratio but can afford bigger errors in the extreme cases of low and high concentration ratios since big errors in these values will not result in false predictions.

The fluorescence properties of Cy7 and Cy7.5 probes are not identical to one specific probe developed for AD (presented in Section 1). Cy7 has absorption/emission peaks at 750/773 nm, an extinction coefficient of 199,000 [M⁻¹cm⁻¹] and quantum yield of 0.3. Cy7.5 has absorption/emission peaks at 788/808 nm and an extinction coefficient of 223,000 [M⁻¹cm⁻¹]. When comparing the fluorescent properties of the AD probes we see some differences in the absorption/emission peaks but similar orders of magnitudes of the extinction coefficient and quantum yields. For example, AOI987, which was used for imaging Aβ, has an absorption/emission peaks at 650/670 nm, an extinction coefficient of 64,570 [M⁻¹cm⁻¹], and a quantum yield of 0.4. THK-265 showed similar properties—absorption/emission peak at 630/650 nm, extinction coefficient of 96,198 [M⁻¹cm⁻¹], and quantum yield of 0.38. CRANAD-58 has a similar absorption peak in 630 nm but an emission peak in 750 nm in the presence of Aβ. For tau imaging, CyDPA2 was presented with an absorption/emission peaks at 826/833 nm, extinction coefficient of 113,553 [M⁻¹cm⁻¹] and quantum yield of 0.049. The differences in the absorption/emission spectra between the fluorescent probes used in this study and the AD probes may affect the accuracy of the concentration ratio estimation. If the changes between the absorption spectra of the Ab and tau probes are big, the assumption that the
optical properties are similar is less accurate. On the other hand, if the two probes have completely separate spectra, the possibility of unwanted excitation of the tau probe when one wants to excite only the Ab probe will be significantly reduced. This phenomenon is one of the problems we had to deal with during our experiments. The absorption spectra of Cy7 and Cy7.5 partly overlapped, causing excitation of both probes together when we needed to measure the fluorescence of each one of them separately. Despite the use of filters for fluorescence emission collection, the combined excitation increased the intensity of the measured fluorescence and possibly contributed to some of the errors.

One of the main advantages of the proposed method, compared to other methods, which measure concentrations in vivo, is that it does not require a priori knowledge regarding the tissue anatomical and optical properties. It is true that measuring the concentrations of amyloid beta and α- tau directly from a collected CSF sample will probably result in a better accuracy. However, this will require performing a lumbar puncture procedure. In our method, as opposed to the lumbar puncture, there is no need to penetrate the dura and collect CSF samples, and the risks and side effects are significantly reduced.

These risks may be further reduced by adding a feedback system to our method, which will provide real-time information regarding the location of the needle and its distance from the dura matter and the CSF. This feedback system, as we have shown, is based on the time-resolved intensity curves, by extracting the values of $t_{\text{max}}$ and the slope, thus enabling accurate estimation of the absolute value of the needle distance from the CSF. The accuracy of the estimation may be increased by taking multiple time-resolved intensity measurements during the insertion of the needle into the lumbar section. The needle distance may then be estimated without a priori knowledge of the tissue’s optical properties.

In addition, once a fluorescence signal is detected, with a sufficient intensity that ensures a good signal to noise ratio, further insertion of the needle may be stopped. The system will evaluate the concentration ratio and the needle distance from the CSF and may indicate to the physician how to continue. If the distance is big enough and the signal to noise ratio is still poor, the system will indicate to the user to continue to push in the needle. In case that the estimated distance between the needle and the CSF is too small the system will indicate the physician to stop additional insertion in order to reduce the risk of dura penetration. We demonstrated the ability to accurately estimate the concentration ration of two fluorescent probes underlying a tissue with a thickness of up to 5 mm. Therefore, we assume that the system may alert the user of being close to the dura in an estimated distance of 3 mm, thus avoiding penetration of the dura even with distance estimation errors of several hundreds of percent but with estimating the concertation ratio with a rather high accuracy.

5. Conclusions

We have demonstrated the possibility to accurately estimate the concentration ratio of two fluorescent probes implanted several millimeters under the skin in living mice. This study has a higher complexity than our previous study, which tested the estimating accuracy in vitro and ex vivo. Here the concentration ratio estimation takes into account the absorption and scattering spectra of an in vivo tissue, pulsatile blood flow and respiration movements. It is a preparation for in vivo studies that will be performed on AD mice models with markers injected to the blood and reaching the CSF. The proposed method may estimate in the future the CSF Aβ42:P-tau ratio without the need to penetrate the dura matter and collect CSF samples. It does not require any a priori information regarding the anatomical and optical properties of the lumbar tissue. Considering these advantages, this technique could be used as an annual test, which may assist in early AD diagnosis and increase the efficacy of treatments. In recent years there are reports on additional potential CSF bio-markers that may be used as early detection [35,36]. Our method is generic and only relies on having a fluorescence marker that can be attached to those disease markers. Therefore, our proposed method can also function on other Alzheimer’s disease markers, so it will be even more powerful than relying on the ratio of the two markers that we have discussed in this work.
**Author Contributions:** O.H. performed all the experiments, calculations, and simulations in this paper. M.E. helped with the animal experiments. I.G. is the head of the group. He initiated the research and advised O.H., who was his doctorate student at the time.

**Funding:** “The founding sponsor (A small stipend to support Osnat Harbater) had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results”.

**Acknowledgments:** Osnat Harbater acknowledges the generous support of the Israeli Ministry of Science and Technology and the support of the Herczeg Institute on Aging for this research. We also thank Yona Keisari from the Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, for his advice during the animal studies.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. *Alzheimers Dement. J. Alzheimers Assoc.* 2017, 13, 325–373.
2. Shaw, L.M.; Vanderstichele, H.; Knapik Czajka, M.; Clark, C.M.; Aisen, P.S.; Petersen, R.C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. *Ann. Neurol.* 2009, 65, 403–413. [CrossRef] [PubMed]
3. Hansson, O.; Zetterberg, H.; Buchhave, P.; Londos, E.; Blennow, K.; Minthon, L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. *Lancet Neurol.* 2006, 5, 228–234. [CrossRef]
4. Buchhave, P.; Minthon, L.; Zetterberg, H.; Wallin, Å.K.; Blennow, K.; Hansson, O. Cerebrospinal Fluid Levels of [beta]-Amyloid 1–42, but Not of Tau, Are Fully Changed Already 5 to 10 Years before the Onset of Alzheimer Dementia. *Arch. Gen. Psychiatry* 2012, 69, 98–106. [CrossRef] [PubMed]
5. Andreasen, N.; Vanmechelen, E.; Vanderstichele, H.; Davidsson, P.; Blennow, K. Cerebrospinal fluid levels of total tau, phospho tau and A 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment. *Acta Neurol. Scand.* 2003, 107, 47–51. [CrossRef]
6. Mattsson, N.; Zetterberg, H.; Hansson, O.; Andreasen, N.; Parnetti, L.; Jonsson, M.; Herukka, S.K.; van der Flier, W.M.; Blankenstein, M.A.; Ewers, M.; et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA* 2009, 302, 385–393. [CrossRef] [PubMed]
7. Boon, J.; Abrahams, P.H.; Meiring, J.H.; Welch, T. Lumbar puncture: Anatomical review of a clinical skill. *Clin. Anat.* 2004, 17, 544–553. [CrossRef] [PubMed]
8. Chernomordik, V.; Hattery, D.; Gannot, I.; Gandjbakhche, A.H. Inverse method 3-D reconstruction of localized in vivo fluorescence—Application to Sjogren syndrome. *IEEE J. Sel. Top. Quantum Electron.* 1999, 5, 930–935. [CrossRef]
9. Eidsath, A.; Chernomordik, V.; Gandjbakhche, A.; Smith, P.; Russo, A. Three-dimensional localization of fluorescent masses deeply embedded in tissue. *Phys. Med. Biol.* 2002, 47, 4079. [CrossRef] [PubMed]
10. Gannot, I.; Garashi, A.; Gannot, G.; Chernomordik, V.; Gandjbakhche, A. In vivo quantitative three-dimensional localization of tumor labeled with exogenous specific fluorescence markers. *Appl. Opt.* 2003, 42, 3073–3080. [CrossRef] [PubMed]
11. Gannot, I.; Garashi, A.; Chernomordik, V.; Gandjbakhche, A. Quantitative optical imaging of the pharmakocinetics of fluorescent-specific antibodies to tumor markers through tissueulike turbid media. *Opt. Lett.* 2004, 29, 742–744. [CrossRef] [PubMed]
12. D’Andrea, C.; Spinelli, L.; Comelli, D.; Valentinii, G.; Cubeddu, R. Localization and quantification of fluorescent inclusions embedded in a turbid medium. *Phys. Med. Biol.* 2005, 50, 2313. [CrossRef] [PubMed]
13. Han, S.-H.; Farshchi-Heydari, S.; Hall, D.J. Analytical method for the fast time-domain reconstruction of fluorescent inclusions in vitro and in vivo. *Biophys. J.* 2010, 98, 350–357. [CrossRef] [PubMed]
14. Hall, D.J.; Sunar, U.; Farshchi-Heydari, S.; Han, S.H. In vivo simultaneous monitoring of two fluorophores with lifetime contrast using a full-field time domain system. *Appl. Opt.* 2009, 48, D74–D78. [CrossRef] [PubMed]
15. Graves, E.E.; Yessayan, D.; Turner, G.M.; Weissleder, R.; Ntziachristos, V. Validation of in vivo fluorochrome concentrations measured using fluorescence molecular tomography. *J. Biomed. Opt.* 2015, 10, 044019. [CrossRef] [PubMed]
16. Lee, J.; Sevick-Muraca, E.M. Three-dimensional fluorescence enhanced optical tomography using referenced frequency-domain photon migration measurements at emission and excitation wavelengths. *JOSA A* 2002, 19, 759–771. [CrossRef] [PubMed]
17. Godavarty, A.; Sevick-Muraca, E.M.; Eppstein, M.J. Three-dimensional fluorescence lifetime tomography. *Med. Phys.* **2005**, *32*, 992–1000. [CrossRef] [PubMed]

18. Yuan, B.; Zhu, Q. Separately reconstructing the structural and functional parameters of a fluorescent inclusion embedded in a turbid medium. *Opt. Express* **2006**, *14*, 7172–7187. [CrossRef] [PubMed]

19. Joshi, A.; Rasmussen, J.C.; Sevick-Muraca, E.M.; Wareing, T.A.; McGhee, J. Radiative transport-based frequency-domain fluorescence tomography. *Phys. Med. Biol.* **2008**, *53*, 2069. [CrossRef] [PubMed]

20. Raymond, S.B.; Boas, D.A.; Bacskai, B.J.; Kumar, A.T. Lifetime-based tomographic multiplexing. *J. Biomed. Opt.* **2010**, *15*, 046011. [CrossRef] [PubMed]

21. Soubret, A.; Ripoll, J.; Ntiashchristos, V. Accuracy of fluorescent tomography in the presence of heterogeneities: Study of the normalized Born ratio. *IEEE Trans. Med. Imaging* **2005**, *24*, 1377–1386. [CrossRef] [PubMed]

22. Sinaasappel, M.; Sterenborg, H. Quantification of the hematoporphyrin derivative by fluorescence measurements using dual-wavelength excitation and dual-wavelength detection. *Appl. Opt.* **1993**, *32*, 541–548. [CrossRef] [PubMed]

23. Raymond, S.B.; Skoch, J.; Hills, I.D.; Nesterov, E.E.; Swager, T.M.; Bacskai, B.J. Smart optical probes for near-infrared fluorescence imaging of Alzheimer’s disease pathology. *Eur. J. Nucl. Med. Mol. Imaging* **2008**, *35*, 93–98. [CrossRef] [PubMed]

24. Hintersteiner, M.; Enz, A.; Frey, P.; Jaton, A.L.; Kinzy, W.; Kneuer, R.; Neumann, U.; Rudin, M.; Staufenbiel, M.; Stoeckli, M.; et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. *Nat. Biotechnol.* **2005**, *23*, 577–583. [CrossRef] [PubMed]

25. Zhang, X.; Tian, Y.; Li, Z.; Tian, X.; Sun, H.; Liu, H.; Moore, A.; Ran, C. Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer’s Disease. *J. Am. Chem. Soc.* **2013**, *135*, 16397–16409. [CrossRef] [PubMed]

26. Okamura, N.; Mori, M.; Furumoto, S.; Yoshikawa, T.; Harada, R.; Ito, S.; Fujikawa, Y.; Arai, H.; Yanai, K.; Kudo, Y. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. *J. Alzheimers Dis.* **2011**, *23*, 37–48. [PubMed]

27. Schmidt, A.; Pahnke, J. Efficient Near-Infrared in Vivo Imaging of Amyloid-β Deposits in Alzheimer’s Disease Mouse Models. *J. Alzheimers Dis.* **2012**, *30*, 651–664. [PubMed]

28. Cui, M.; Ono, M.; Watanabe, H.; Kimura, H.; Liu, B.; Saji, H. Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of β-Amyloid Deposits. *J. Am. Chem. Soc.* **2014**, *136*, 3388–3394. [CrossRef] [PubMed]

29. Maruyama, M.; Shimada, H.; Suhara, T.; Shinotoh, H.; Ji, B.; Maeda, J.; Zhang, M.R.; Trojanowskij, J.Q.; Lee, V.M.Y.; Ono, M.; et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. *Neuron* **2013**, *79*, 1094–1108. [CrossRef] [PubMed]

30. Kim, H.-Y.; Sengupta, U.; Shao, P.; Guerrero-Muñoz, M.J.; Kayed, R.; Bai, M. Alzheimer’s disease imaging with a novel Tau targeted near infrared ratiometric probe. *Am. J. Nucl. Med. Mol. Imaging* **2013**, *3*, 102. [PubMed]

31. Harbater, O.; Gannot, I. Fluorescent probes concentration estimation in vitro and ex vivo as a model for early detection of Alzheimer’s disease. *J. Biomed. Opt.* **2014**, *19*, 127007. [CrossRef] [PubMed]

32. Ran, C.; Xu, X.; Raymond, S.B.; Ferrara, B.J.; Neal, K.; Bacskai, B.J.; Medarova, Z.; Moore, A. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. *J. Am. Chem. Soc.* **2009**, *131*, 15257–15261. [CrossRef] [PubMed]

33. Firbank, M.; Delpy, D. A design for a stable and reproducible phantom for use in near infra-red imaging and spectroscopy. *Phys. Med. Biol.* **1993**, *38*, 847. [CrossRef] [PubMed]

34. Jacques, S.L. Optical properties of biological tissues: A review. *Phys. Med. Biol.* **2013**, *58*, R37. [CrossRef] [PubMed]

35. Galasko, D. Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-Targeted Approaches. *Front. Neurol.* **2015**, *6*, 256. [CrossRef] [PubMed]

36. Sharma, N.; Anshika, N.S. Exploring Biomarkers for Alzheimer’s Disease. *JCDR* **2016**, *10*, KE01. [CrossRef] [PubMed]